Jundishapur Journal of Microbiology

Published by: Kowsar

Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran

Mozhgan Afrasiabi 1 , Seyed Younes Hosseini 1 , * , Ramin Yaghobi 2 , * , Mohammad-Reza Fattahi 1 , Maryam Ardebili 1 and Mahboobeh Khodadad 1
Authors Information
1 Gastroenterohepatology Research Center (GEHRC), Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Corresponding Authors:
Article information
  • Jundishapur Journal of Microbiology: October 01, 2015, 8 (10); e24965
  • Published Online: October 29, 2015
  • Article Type: Research Article
  • Received: October 28, 2014
  • Revised: February 3, 2015
  • Accepted: February 28, 2015
  • DOI: 10.5812/jjm.24965

To Cite: Afrasiabi M, Hosseini S Y, Yaghobi R, Fattahi M, Ardebili M, et al. Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran, Jundishapur J Microbiol. 2015 ; 8(10):e24965. doi: 10.5812/jjm.24965.

Abstract
Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med. 2005; 8(2): 84-90
  • 2. Vermehren J, Sarrazin C. New HCV therapies on the horizon. Clin Microbiol Infect. 2011; 17(2): 122-34[DOI][PubMed]
  • 3. Courcambeck J, Bouzidi M, Perbost R, Jouirou B, Amrani N, Cacoub P, et al. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir Ther. 2006; 11(7): 847-55[PubMed]
  • 4. Kim AY, Timm J, Nolan BE, Reyor LL, Kane K, Berical AC, et al. Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual. J Infect Dis. 2009; 199(5): 737-41[DOI][PubMed]
  • 5. Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol. 2007; 13(43): 5673-81[PubMed]
  • 6. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother. 2010; 65(2): 202-12[DOI][PubMed]
  • 7. Romano KP, Ali A, Royer WE, Schiffer CA. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A. 2010; 107(49): 20986-91[DOI][PubMed]
  • 8. Fields B, Knipe D, Howley PM. Fields virology. 2013;
  • 9. Mayhoub AS. Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorg Med Chem. 2012; 20(10): 3150-61[DOI][PubMed]
  • 10. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol. 2007; 13(17): 2416-26[PubMed]
  • 11. Neau D, Jouvencel AC, Legrand E, Trimoulet P, Galperine T, Chitty I, et al. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients. J Med Virol. 2003; 71(1): 41-8[DOI][PubMed]
  • 12. Vallet S, Gouriou S, Nousbaum JB, Legrand-Quillien MC, Goudeau A, Picard B. Genetic heterogeneity of the NS3 protease gene in hepatitis C virus genotype 1 from untreated infected patients. J Med Virol. 2005; 75(4): 528-37[DOI][PubMed]
  • 13. Lopez-Labrador FX, Moya A, Gonzalez-Candelas F. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. Antivir Ther. 2008; 13(4): 481-94[PubMed]
  • 14. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology. 2008; 48(6): 1769-78[DOI][PubMed]
  • 15. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J. 2013; 10: 355[DOI][PubMed]
  • 16. Zeminian LB, Padovani JL, Corvino SM, Silva GF, Pardini MI, Grotto RM. Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors. Mem Inst Oswaldo Cruz. 2013; 108(1): 13-7[PubMed]
  • 17. Winters MA, Chary A, Eison R, Asmuth D, Holodniy M. Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. J Med Virol. 2010; 82(5): 791-8[DOI][PubMed]
  • 18. Vicenti I, Rosi A, Saladini F, Meini G, Pippi F, Rossetti B, et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J Antimicrob Chemother. 2012; 67(4): 984-7[DOI][PubMed]
  • 19. Colson P, Brouk N, Lembo F, Castellani P, Tamalet C, Gerolami R. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient. Hepatology. 2008; 47(2): 766-7[DOI][PubMed]
  • 20. Peres-da-Silva A, de Almeida AJ, Lampe E. Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naive patients. Arch Virol. 2010; 155(5): 807-11[DOI][PubMed]
  • 21. Vallet S, Viron F, Henquell C, Le Guillou-Guillemette H, Lagathu G, Abravanel F, et al. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther. 2011; 16(7): 1093-102[DOI][PubMed]
  • 22. Trevino A, de Mendoza C, Parra P, Rodriguez C, Madejon A, Plaza Z, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther. 2011; 16(3): 413-6[DOI][PubMed]
  • 23. Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol. 2015; 28(1): 55-65[PubMed]
  • 24. Paolucci S, Fiorina L, Piralla A, Gulminetti R, Novati S, Barbarini G, et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J. 2012; 9: 245[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments